This is the rare longevity supplement where the most-cited human trial flagged a problem instead of a benefit. Blood pressure does drop at the high dose; LDL cholesterol goes up by enough to matter. Cost is low, effort is low — but the headline reason to take it, the longevity mechanism, has not landed in a single human trial. Reading this once and crossing it off the list is the cheapest move.
What's in the capsule is a chemically tweaked version of resveratrol — two small swaps that replace fragile parts of the molecule with stable ones. The fix matters: most oral resveratrol is destroyed in the gut and liver before it ever reaches the bloodstream, and pterostilbene survives that gauntlet at roughly four times the rate — though that number is from rat work, not human (Kapetanovic 2011). What it does once inside is the same story resveratrol tells: it activates SIRT1 and AMPK, two of the body's main fuel-and-stress sensors that flip cells into repair-and-conserve mode (McCormack 2013). It crosses into the brain, suppresses inflammatory signalling, and nudges mitochondrial output upward in cell and animal studies (Dutta 2023). The mechanism is plausible. The leap — and it is the leap every supplement category in this neighbourhood has stumbled on — is whether anything visible in a dish or a rodent translates into anything a human notices.
What the human trials actually show
There is exactly one well-powered human trial on pterostilbene by itself, and one cleaner follow-up on pterostilbene stacked with a NAD+ precursor. Both are worth knowing in detail before you reach for the bottle.
The second trial picked a hard target: muscle recovery from injury, in 55- to 80-year-olds — exactly the demographic longevity marketing aims at. For six weeks, half the group took 200 mg pterostilbene plus 1,000 mg nicotinamide riboside daily; the other half took placebo. Blood NAD+ levels in the supplement group rose substantially and stayed there — the biochemical target was hit, cleanly and reproducibly. Muscle strength after the induced injury: no difference. Soreness scores: no difference. Stem cell content in the muscle tissue: no difference. Histology: no difference. Functionally, the result was zero (Jensen 2022).
The cognition claims that anchor most pterostilbene marketing aren't extrapolated from a human trial. They're extrapolated from aged rats and from the SAMP8 accelerated-aging mouse, which do show improvements in working memory and inflammation markers under chronic dosing (Dutta 2023). No equivalent human trial has been published. The longevity claims are in the same shape: real mechanism, encouraging animal data, no human evidence at all.
"Better resveratrol" is two leaps in one sentence
The marketing line goes: pterostilbene survives digestion four times better than resveratrol, therefore it's the upgraded version, therefore the longevity benefits show up at four times the strength. That's two leaps stacked on top of each other. The bioavailability number is real but it's measured in rats (Kapetanovic 2011) — the human comparison hasn't been done head-to-head. And higher blood levels of a compound aren't a clinical outcome; they're a precondition for one. The most-tested human longevity-supplement story of the last twenty years is resveratrol itself, and its major human trials in aging endpoints came back null. Inheriting that mechanism with more reliable absorption is not, on present evidence, inheriting any benefit a person can feel.
If you take it anyway
The Riche safety trial cleared 250 mg/day on liver, kidney, and blood-sugar markers — that ceiling is what the FDA's generally-recognized-as-safe notification rests on (Riche 2013). Typical commercial doses run 50 to 250 mg/day, split between morning and evening, with a meal that has some fat in it (the molecule is fat-soluble; absorption drops on an empty stomach). Bare capsules cost roughly $15-40 a year; branded longevity stacks that bundle it with a NAD+ precursor push past $300.
What you're actually trading
The trade is small in both directions. Take it: you spend $30 to $500 a year (the bare capsule versus a branded stack), swallow another pill in the morning, and accept a real chance of a lipid panel that drifts the wrong way in exchange for an unknown chance of a longevity benefit no human trial has yet measured (Riche 2014). Skip it: you save the money and the lipid risk, and you forgo a plausible cellular-signalling tool that, in the only direct functional test of its target demographic, did nothing visible (Jensen 2022).
Six months from now, neither version of you will look obviously different from the other. A year out, the version who took it might have a slightly worse lipid panel — or might not, if a statin is already doing the work. The version who skipped it has $30 to $500 in the bank and one fewer item on the supplement shelf, and the same shape of cognitive trajectory the trials would have predicted either way. That is, on the present evidence, the honest forecast.
Adjacent topics worth knowing: resveratrol, the parent compound pterostilbene is the methylated upgrade of, and nicotinamide riboside (or NMN) — the NAD+ precursors pterostilbene is most often stacked with. Both have their own large but unconvincing human evidence bases, and the same shape of mechanism-rich, outcome-thin story this one does.
Substance and claimed effects
Pterostilbene is a methylated stilbene — chemically 3,5-dimethoxy-4'-hydroxystilbene, the dimethyl ether analog of resveratrol — found naturally in blueberries (roughly 100-500 ng per gram of fresh fruit), grapes, and the heartwood of the Indian Kino tree (Pterocarpus marsupium). Sold as a 50-250 mg/day capsule for longevity, metabolic, cognitive, and anti-inflammatory benefit, often as part of NAD+-booster stacks (Elysium Basis pairs 50 mg pterostilbene with 250 mg nicotinamide riboside). Vendor claims span SIRT1/AMPK-mediated longevity signalling, blood-pressure reduction, cognitive support in aging, anti-inflammatory action via NF-κB, glycemic control, and "better resveratrol" lipid handling. This entry covers each — particularly the consequence the prevailing literature most clearly establishes in humans: an LDL increase that complicates the cardiometabolic case (Riche 2014).
Evidence by addressing question
Mechanism
Pterostilbene activates the SIRT1 deacetylase and AMPK kinase, the two longevity-sensor pathways that resveratrol also targets. Downstream consequences include PGC-1α activation, mitochondrial biogenesis, and reduced reactive oxygen species (McCormack & McFadden 2013). Methylation of resveratrol's hydroxyls produces two clinically relevant differences: lipophilicity rises sharply (improved membrane permeability and brain penetration in preclinical models), and the phase-II glucuronidation that destroys most oral resveratrol is partially bypassed (Dutta et al. 2023). In the only head-to-head pharmacokinetic comparison, oral bioavailability in rats was approximately 80% for pterostilbene versus approximately 20% for resveratrol, with plasma exposure of the parent compound an order of magnitude higher (Kapetanovic et al. 2011). Anti-inflammatory effects in cell and animal models trace to NF-κB suppression: pterostilbene reduces phosphorylation of IκBα and IKK-α/β, lowering nuclear p65 translocation and downstream TNF-α, IL-6, and nitric oxide (McCormack & McFadden 2013). A separate mechanistic strand connects to the lipid signal: in HL-1 cardiomyocytes, pterostilbene increased LDL-receptor expression and uptake via PCSK9/SREBP2 modulation — a story consistent with the human LDL data going either direction depending on receptor location and tissue compartment.
Evidence
The only well-powered human efficacy trial is the Riche group's RCT: 80 hypercholesterolemic adults across four arms — placebo, 100 mg/day pterostilbene, 250 mg/day pterostilbene, or 100 mg/day pterostilbene plus 200 mg/day grape extract — split twice daily, for 6-8 weeks. The high-dose arm dropped systolic blood pressure by −7.8 mmHg (P < 0.01) and diastolic by −7.3 mmHg (P < 0.001) — a clinically meaningful reduction in the range of a low-dose antihypertensive. But LDL cholesterol rose by +17.1 mg/dL in the pterostilbene-monotherapy pooled groups (P = 0.001), an effect not seen when grape extract was co-administered. Subjects on a statin at baseline did not show the LDL rise (Riche et al. 2014). The companion safety paper from the same cohort found no signal on liver enzymes, creatinine, or glucose at 250 mg/day and supported the FDA GRAS notifications that followed (Riche et al. 2013).
The second well-controlled trial is Jensen et al.: 32 elderly subjects (55-80) randomized to NRPT (1,000 mg/day nicotinamide riboside + 200 mg/day pterostilbene) or placebo for 6 weeks around an experimentally induced muscle injury. NRPT raised whole-blood NAD+ substantially and reproducibly — and failed every primary endpoint: no improvement in muscle stem cell content, strength recovery, soreness scores, or histological regeneration markers (Jensen et al. 2022). This is the clearest functional test of the NAD+-pterostilbene stack to date and it was negative despite reliable target engagement.
Human cognition evidence is absent. Animal cognition evidence is encouraging: aged rats on pterostilbene outperform controls on working-memory tasks and the SAMP8 accelerated-aging mouse shows cognitive improvement with markers of reduced cellular stress and neuroinflammation (Dutta et al. 2023). Human longevity evidence is absent — the available data are surrogate NAD+ measurements, not hard endpoints. Cancer-prevention evidence is preclinical only.
Protocol
Commercial doses span 50-250 mg/day. The Riche 2014 trial used 100 mg (low) and 250 mg (high) split BID (Riche et al. 2014). Elysium Basis stacks 50 mg pterostilbene with 250 mg nicotinamide riboside once daily. Pterostilbene is lipophilic and absorption is improved with a fatty meal. No human dose-response curve has been published; the 250 mg/day ceiling carries forward from the safety trial (Riche et al. 2013).
Contraindications
No specific drug-interaction or population-level contraindications are well documented. Pregnancy and lactation: untested. The LDL signal warrants caution in anyone with baseline dyslipidemia who is not already on a statin — the statin subgroup in Riche 2014 was protected from the LDL rise, but the rest of the cohort was not (Riche et al. 2014). The grape-extract co-administration attenuated the lipid effect in the trial but no follow-up has confirmed the protection.
Misconceptions
"Pterostilbene is just a better resveratrol because of bioavailability." Higher plasma exposure is not a clinical outcome. The bioavailability advantage was measured in rats (Kapetanovic et al. 2011); the only well-powered human efficacy trial showed mixed signal with an adverse lipid component (Riche et al. 2014). Marketing pages routinely transpose preclinical resveratrol mechanisms (sirtuin activation, mitochondrial biogenesis, cancer prevention) onto pterostilbene as if the human evidence were equivalent. It is not. "NAD+ booster stacks work." NRPT supplementation reliably raises blood NAD+. In the cleanest functional test to date, that NAD+ rise translated to nothing measurable (Jensen et al. 2022).
Practicalities
Available widely as a standalone capsule (typically 50-150 mg) or as part of a longevity stack. Bulk standalone pricing is roughly $15-40/year at 100-250 mg/day; brand-name stacks (Basis, Tru Niagen and analogs) run $300-600/year. Standardised trans-pterostilbene (the bioactive isomer) from reputable manufacturers carries third-party purity testing; the dietary supplement market is otherwise unregulated for content.
Failure modes
The well-documented failure is LDL elevation in subjects not on statin therapy (Riche et al. 2014). The undocumented failure mode is the assumption that "more bioavailable resveratrol" carries the resveratrol claim portfolio into the clinic — a leap the human evidence does not support, and that resveratrol itself has repeatedly failed in human RCTs of aging endpoints.
Stakes
Continuing to take pterostilbene without monitoring trades a known adverse lipid signal for unproven longevity benefit. Continuing to skip it forgoes a plausible cellular-signalling molecule that the human evidence has not yet shown does anything beneficial outside of blood pressure at the highest tested dose. Neither side of this trade is large.
Out of scope
Resveratrol (the parent compound, with its own large but unconvincing human trial portfolio) and nicotinamide riboside / NMN (the NAD+ precursor story, frequently stacked) are adjacent entries.
History
Identified in Pterocarpus marsupium heartwood in 1940 and used in Ayurvedic medicine for diabetes long before isolation. Brought into Western longevity research as part of the resveratrol-analog wave following Sinclair's early 2000s SIRT1 work. Commercialised through ChromaDex's pTeroPure ingredient in the early 2010s and Elysium Basis (launched 2014, advised by NAD+ researcher Leonard Guarente). ChromaDex stopped taking new pterostilbene orders after the Riche 2014 LDL data was published, citing the cholesterol signal.
The credibility range
Optimist case
Pterostilbene replicates the resveratrol mechanism portfolio (SIRT1, AMPK, PGC-1α, NF-κB) with four-fold higher bioavailability, brain penetration, and a clean safety profile up to 250 mg/day across hepatic, renal, and glycemic markers (Riche et al. 2013). Animal data on cognitive aging is consistent across multiple models. The systolic and diastolic blood pressure reductions in Riche 2014 are clinically meaningful and reproducible in mechanism. The LDL increase is reversed when co-administered with grape extract, suggesting a co-formulation path. The Jensen muscle-injury trial chose a hard acute-recovery endpoint that any chronic-use longevity supplement might be expected to miss. For someone optimising on longevity priors, a plausible mechanism plus animal cognition plus measured BP reduction at ~$30/year is a defensible bet.
Skeptic case
One human efficacy trial in 80 subjects is not an evidence base. The only direct human lipid measurement showed pterostilbene raised LDL by 17.1 mg/dL — directionally the opposite of what a cardiometabolic supplement should do (Riche et al. 2014). The Jensen 2022 NRPT trial was a clean test of NAD+-mediated functional benefit in the target demographic and failed every endpoint despite reliable target engagement (Jensen et al. 2022). No human trial has tested cognition; no human trial has tested longevity. The mechanism extrapolation from resveratrol is precisely the preclinical-to-human leap that resveratrol itself has repeatedly failed to clear in controlled trials. Commercial incentives are strong: pterostilbene anchored a multi-million-dollar supplement category before any positive human efficacy trial supported the central claims.
Author's call
Pterostilbene is a plausible molecule with thin and mixed human evidence and a clearly documented adverse signal on LDL cholesterol. The longevity case is preclinical extrapolation; the one cardiovascular signal cuts in two directions (BP down, LDL up); the one rigorous functional trial in the target demographic was negative. This is a "decide" entry, not a "do" entry — and readers with baseline dyslipidemia who are not on a statin should be especially cautious. Evidence score 2; controversy score 3.
Stakeholder and incentive map
- Supplement makers and longevity brands (Elysium Health, NOVOS, ChromaDex/pTeroPure originators) pushed pterostilbene as both a standalone and as a NAD+-stack component for most of the last decade.
- Academic longevity researchers (Guarente and adjacent NAD+ groups) legitimised the category through advisory roles, even as the human efficacy evidence lagged the commercial rollout.
- Skeptics include independent clinical nutritionists and the editorial responses to Riche 2014 that triggered ChromaDex's halt on new pterostilbene orders.
- Regulatory side: GRAS notification accepted at 250 mg/day; no FDA drug approval; sold as a dietary supplement, with the labelling latitude that implies.
Population variability
The only direct human efficacy data is in hypercholesterolemic adults (Riche et al. 2014), so generalisation to healthy populations is uncertain. The LDL effect was absent in the statin subgroup and attenuated by grape-extract co-administration. The NRPT muscle-injury trial enrolled 55-80 year-olds — the explicit "longevity" target demographic — and showed no functional benefit (Jensen et al. 2022). No published data in young healthy adults. No sex-stratified efficacy data. The animal cognition data is exclusively in aged rodents (Dutta et al. 2023).
Knowledge gaps
What hasn't been studied in humans: chronic (more than 8 weeks) supplementation on any endpoint; cognition in any population; cardiovascular hard endpoints; longevity surrogates beyond NAD+. The LDL question needs replication — the Riche finding is mechanistically corroborated in cardiomyocyte work but no second well-powered RCT has measured the same outcome. What would change the call: a positive 6-12 month cognitive RCT in healthy aging adults; a confirmation or refutation of the LDL signal in a non-hypercholesterolemic cohort; any hard-endpoint cardiovascular data; a positive functional readout from NAD+ supplementation in a well-controlled trial.
Brief coverage. The input description named blood lipids, blood sugar, inflammation, cognition, and cellular-aging pathways. All five are touched in the article. The honest weighting: the LDL signal from Riche 2014 is the single most consequential finding in the human evidence base, so lipids carry the most weight (in the dek, the science callout, the warning, and the stakes section). Blood sugar gets one line in the science callout because there was no signal to discuss. Cognition and cellular-aging are scoped as "mechanism is plausible, no human evidence" — not silently dropped, but honestly framed. Inflammation is folded into the mechanism paragraph rather than given its own section, because no human anti-inflammatory trial exists.
Hard scoring calls.
evidence: 2— Riche 2014 is a real RCT (n=80) with mixed primary outcomes, Jensen 2022 is well-controlled and negative on every endpoint despite reliable target engagement, and safety is well-established. That fits "sparse or contested literature; mechanism plausible but trials thin or mixed" better than the "small or preliminary studies" of evidence-3.controversy: 3— ChromaDex stopped taking new pterostilbene orders after the Riche LDL finding while Elysium and adjacent longevity brands continued promoting it. Active expert disagreement, not just minor pushback.longevity: 1andhealth_short_term: 1— both are marginal scores rather than zeros because the mechanism is genuinely plausible and BP did drop at 250 mg/day. But the LDL signal cuts directly against the cardiovascular case, so a 2 would overstate the human evidence.action: deciderather thandooravoid— the evidence is not strong enough either to recommend the supplement or to actively warn off; the LDL question is a real tradeoff a reader should weigh, ideally with a lipid panel before and after.cadence: dailyreflects what the reader does if they decide to take it.applicability: 2— niche to the longevity-supplement-considering slice of adults, not a universal health concern.
Dream narrative. Written despite the overall score (≈10) being well below the 40 obligation threshold, because the honest hook is the relief / clarity lever — the version of the reader who saw the evidence in time, stopped paying for it, and freed the mental real estate. A "skip it" entry still earns a brief narrative when relief is the genuine payoff.
Citation library note. The Riche2014 entry's stored title accidentally merges the safety-paper title with the metabolic-parameters paper's subtitle (author error at add_citation time; no update tool was available). The DOI is correct (10.1155/2014/459165 → "Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial"), so all article citations resolve to the right paper. Flagging for a future librarian pass.
Future-link candidates. Adjacent entries that don't exist yet but this one should cross-link to once they do: resveratrol, nicotinamide riboside, NMN, and a general NAD+ booster category entry. A statin decision entry would be relevant to the LDL warning, since the trial's statin-using subgroup was protected.
Separate-entry candidates. The NRPT / NAD+-precursor story is its own entry's worth of material — Jensen 2022 is cited here as the cleanest functional test of pterostilbene + NR together, but the broader NAD+ supplementation question belongs in an NR / NMN entry.
Pterostilbene
Bulk standalone pterostilbene capsules run roughly $15-40/year at 100-250 mg/day. Branded longevity stacks (Basis, etc.) push to $300-600/year.
One or two capsules a day with food. No special timing beyond a fat source for absorption; no required monitoring.
One well-powered human RCT (Riche 2014, n=80, hypercholesterolemic) with mixed primary outcomes; one well-controlled NRPT trial (Jensen 2022, n=32 elderly) that was negative on every functional endpoint despite raising NAD+; safety established up to 250 mg/day (Riche 2013). Mechanism well-characterised in cell and animal models. No human cognitive or longevity data.
Mechanism (SIRT1, AMPK, NF-κB suppression) is plausible for cellular-aging contribution to long-term appearance, but no human trial has measured any skin or aging-trajectory endpoint (Dutta 2023). The LDL signal from Riche 2014 (+17.1 mg/dL) arguably cuts against cumulative vascular health, which itself drives long-term look.
High-dose pterostilbene (250 mg/day) reduced systolic BP by 7.8 mmHg and diastolic by 7.3 mmHg over 6-8 weeks (Riche 2014), a real felt-effect range. The offset: LDL rose by 17.1 mg/dL in the same trial. Net short-term wellness is mixed at best.
Mechanism (SIRT1/AMPK/PGC-1α activation, NF-κB suppression) is plausible (McCormack 2013, Dutta 2023). Human longevity evidence is absent. The Jensen 2022 NRPT trial — the cleanest functional test in the target demographic — was negative on every endpoint despite reliable NAD+ elevation. Score reflects mechanism plus animal data without human confirmation, partially offset by the LDL signal.